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ABSTRACT  
Purpose: To examine the physiological cost when walking in subjects with CFS and a 
matched control group, walking at their preferred and at matched walking speeds.  
Methods: Seventeen people with CFS and 17 matched controls participated in this 
observational study of physiological cost during over-ground gait. Each subject walked for 
five minutes at their preferred walking speed (PWS). Controls then walked for five minutes at 
the same pace of their matched CFS subject. Gait speed and oxygen uptake, gross and net, 
were measured and oxygen uptake was expressed per unit distance ambulated. CFS subjects 
completed the CFS- Activities and Participation Questionnaire (CFS-APQ). 
Results: At PWS the CFS group walked at a slower velocity of 0.84 ±0.21ms-1 compared to 
controls with a velocity of 1.19 ±0.13m·s-1 (P<0.001). At PWS both gross and net oxygen 
uptake of CFS subjects was significantly less than controls (P=0.023 and P=0.025 
respectively). At matched velocity both gross and net physiological cost of gait was greater 
for CFS subjects than controls (P=0.048 and P=0.001 respectively). 
Conclusion: The physiological cost of walking was significantly greater for people with CFS 
compared to healthy subjects. The reasons for these higher energy demands for walking in 
those with CFS have yet to be fully elucidated 
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INTRODUCTION 
Chronic fatigue syndrome (CFS) is a debilitating condition of unknown aetiology and 
disputed pathophysiology, though there is mounting evidence that factors, such as lipid 
peroxidation and immune dysregulation can be involved in the development or maintenance 
of the illness. There are a number of published criteria used to diagnose people with CFS 
however the most commonly used and accepted are the criteria developed by the Centres for 
Disease Control (CDC) [1]. Diagnosis is based on signs and symptoms and exclusion of other 
conditions with similar features e.g. Hypothyroidism. The exact prevalence of CFS is 
difficult to determine but it is thought to be at least 0.2% - 0.4% [2]. Various groups have 
studied the gene expression in peripheral blood of patients with CFS, and from those studies 
the most predominant functional theme is that of immunity and defence. Work is ongoing to 
develop a “gene signature” for the illness [3] which might lead to a more objective diagnostic 
test being available in the future [4]. 
With such an array of clinical features, as defined by the CDC [1], it is not surprising that 
CFS appears to result in significant and lasting functional impairment. Few studies have 
objectively examined these functional limitations, in particular the walking ability of this 
group of patients. Boda et al. [5] analysed subjects’ gait at three different speeds on a 
treadmill and reported that, at slower speeds, those with CFS took smaller and slower steps 
compared to healthy controls. In our initial study we measured the temporal and spatial gait 
parameters of those with CFS and controls using an instrumented walkway [6]. Similar to the 
study by Boda et al. we reported a number of statistically significant differences in the gait 
parameters between the two groups and concluded that those with CFS took smaller and 
slower steps. It was also noted that these differences were still present after a 15 minute 
period of sub-anaerobic exercise. In a subsequent study [7] we confirmed the previous 
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findings but also observed a number of differences between CFS and control subjects in 
terms of kinematic gait parameters when subjects walked at their preferred walking speed. 
However it might have been that the differences we observed were due to the slower walking 
speed of those with CFS and not a manifestation of the condition itself.  
Overall there is objective and repeatable evidence to support the presence of locomotor 
impairment in those with CFS walking at their PWS. It is known that the physiological cost 
of walking is increased in many other pathological conditions with associated locomotor 
impairment, such as stroke [8,9], multiple sclerosis [10] and following lower limb amputation 
[11]. However, it is generally recognised that these higher energy costs may be due to the 
condition itself or simply a reflection of the relatively slow preferred walking speed of most 
patient groups. We were unable to find any previous studies investigating the physiological 
cost of walking in CFS. If indeed the physiological cost of walking is relatively higher in 
those with CFS this may go some way to explain the reduction in the functional abilities of 
the sufferer [12]. 
Therefore the aims of the study were to firstly examine the physiological cost of overground 
walking of subjects with CFS and a group of matched control subjects whilst walking at their 
PWS. Secondly to compare the physiological cost of walking between the two groups when 
the gait speed was matched i.e. when controls walked at the PWS of the CFS person to whom 
they were matched. 
 
Page | 5  
 
METHODS 
Subjects 
Seventeen people (12 females, 5 males) with CFS were recruited from local support groups.  
All subjects had a confirmed medical diagnosis of CFS and at the time of assessment current 
symptoms were examined to ensure the subjects complied with the CDC diagnostic criteria 
for CFS [1].  Our inclusion criteria stipulated that participants had to be aged between 18-65 
years, have no co-morbidity that would restrict gait e.g. musculoskeletal, respiratory 
problems, and be able to walk continuously for a period of 5 minutes with or without a 
walking aid, although no subject chose to use a walking aid.  The control group (12 females, 
5 males) were a convenience sample and were matched to the patient group in terms of age 
and gender. The level of activity for the control participants was recorded using the short self-
administered version of the International Physical Activity Questionnaire (IPAQ) [13].  The 
IPAQ categorises the participants’ level of physical activity into one of three categories; low, 
moderate or high. For this study those with high levels of activity were excluded from taking 
part. The control group ultimately consisted of 6 subjects categorised as having low and 11 
subjects as having moderate levels of activity. 
Ethics 
All subjects were given written information on the study and written, informed consent was 
obtained.  All procedures were approved by Glasgow Caledonian University’s Ethics 
Committee. 
Procedure 
Page | 6  
 
A COSMED K4b2 (Cosmed, Rome, Italy) gas analysis system was used to measure oxygen 
uptake during free walking. Gait speed and distance were measured using a standard stop-
watch and a lap-counter. The gas analysis system was fitted to the participants were then 
were asked to sit at rest for a period of 2mins.  At the end of this period the gait test 
commenced.  
Subjects walked around an elliptical course on a level floor outlined by two cones 9.5m apart.  
This gave a shuttle length of 10m encouraging them to walk at a more consistent pace. For 
each test the participants walked for five minutes and the total distance walked and the time 
taken was recorded.  
All subjects were asked to walk around the cones at their PWS. The control group were then 
given a minimum recovery period of five minutes, during which the COSMED system 
remained in place, and were then requested to walk at the PWS of the CFS patient to which 
they were matched. The matched pace was achieved by providing a tone at the start of each 
repetition, generated using PowerPoint slide transition advance slide facility (Microsoft 
Corporation), of the walking circuit and expecting the control to have completed the circuit 
by the successive bleep.  
Activity and Participation Questionnaires 
CFS subjects completed the Chronic Fatigue Syndrome Activity and Participation 
Questionnaire (CFS-APQ); this is a disease specific questionnaire that measures the activity 
limitations and participation restrictions over the last seven days [14]. Two scores are 
obtained from the questionnaire; the total score (CFS-APQ1), and satisfaction score (CFS-
APQ2). The scores for CFS-APQ1 range from 1 indicating no activity limitations to 16 
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representing very severe activity limitations.  The score for CFS-APQ2 ranges from 1 to 4, 
higher scores indicating more severe activity participation limitations [15]. 
Data Analysis  
Descriptive statistics are presented as means and standard deviations. Age, weight, height and 
Body Mass Index (BMI) of the two groups, patient and control were compared using a paired 
t-test using Minitab version 15 (Minitab Inc.). Distance and duration of the walk were 
recorded. Gross and net oxygen uptake per kg body weight (VO2 kg-1 (mL·min-1·kg-1)) and 
VO2 kg-1 per unit distance walked (physiological cost) (VO2·kg-1·m-1 (mL·min-1·kg-1·m-1) 
was used to analyse metabolic cost of gait. Gross measures are the actual values recorded 
during gait whereas the net measures are the measures taken during gait with the resting 
levels subtracted. The net measures are representative of the individuals’ metabolic 
requirement to undertake gait. The average of these parameters was calculated between 
minutes 3 and 4 of the 5 minute walking period using Excel (Microsoft Corporation). 
Minutes 3-4 were selected as literature suggests that steady state is achieved at this time 
[16,17]. Test data was analysed using a one-way ANOVA using Minitab version 15 (Minitab 
Inc.) and the confidence level set at 95%.
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RESULTS 
 There was no difference in anthropometric data between the CFS and the control group. 
Additionally there was no difference in resting VO2 between the groups (Table 1).   The CFS-
APQ1 measured a median value of 10.6 (range 6.7 – 12.6) and, the CFS-APQ2 a median 
value of 3.0 (range 2.1 – 3.5).  Both scores were on the mid to higher end of the scale 
indicating obvious activity and participation limitations [18]. All CFS subjects were unable to 
work or to undertake further education. Fifteen of the CFS subjects reported that their 
condition was stable and the remaining two reported that their condition was ‘getting worse’. 
 
Table 1 near here 
 
At PWS the CFS group walked with a velocity of 0.84m·s-1 (±0.21ms-1) and controls with a 
velocity of 1.19m·s-1 (±0.13m·s-1) (P<0.001). When the control group were asked to walk at a 
pace equivalent to their matched patient’s velocity the control population walked at a velocity 
of 0.84m·s-1 (±0.21m·s-1) (P=0.236). 
Figure 1 (a-b) shows the gross and net oxygen uptake, (c-d) and gross and net physiological 
cost for both CFS subjects and controls at their PWS and for the controls at the PWS of the 
CFS subjects. At PWS the gross oxygen uptake of CFS subjects was significantly less than 
controls (10.18 ±1.81mL·kg-1, and 11.69 ±1.87mL·kg-1 respectively, P=0.023). When the 
controls walked at the PWS of the CFS subjects the value for controls was significantly lower 
than CFS subjects (8.61 ±1.37mL·kg-1, P = 0.008).   For net oxygen uptake at PWS the results 
for CFS subjects were significantly less than controls (6.97 ±1.73mL·kg-1, and 8.58 
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±1.87mL·kg-1 respectively, P=0.025). At the matched speed, explained above, the values for 
controls were significantly lower than CFS subjects (5.5 ±1.34mL·kg-1, P = 0.002) 
 
Figure 1a - d near here 
 
When the distance subjects walked was considered in relation to gross oxygen uptake, at 
PWS the physiological cost for CFS subjects was significantly greater than the controls (0.21 
±0.05mL·kg-1·m-1 and 0.16 ±0.02mL·kg-1·m-1 respectively, P=0.001). At matched speed the 
values for controls walking at the PWS of the CFS subjects was significantly less than CFS 
subjects at their PWS (0.18 ±0.04mL·kg-1·m-1, P=0.048). For net physiological cost at PWS 
the results for CFS subjects were significantly greater than controls (0.14 ±0.03mL·kg-1m-1, 
and 0.12 ±0.03mL·kg-1m-1) respectively, P=0.012) and again at matched velocity the values 
for controls at the PWS of the CFS subjects was significantly less than CFS subjects at their 
PWS (0.11 ±0.02mL·kg-1m-1, P = 0.001) 
Thus it appears that, at PWS, both groups have a different metabolic oxygen requirement 
both for gross and net measures. The CFS subjects demonstrate a significantly greater 
physiological cost to walk a much shorter distance and thus walk with a much less energy 
efficient gait pattern. At PWS there was a 28% gross and a 17% net increase in metabolic 
cost per unit distance for CFS subjects in comparison to controls. Even when the controls 
were asked to walk at the speed matched to that of the subjects, the physiological cost for the 
CFS subjects remained significantly higher than that of the controls; a 17% gross and a 26% 
net increase in physiological cost for CFS subjects at matched speeds.  
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DISCUSSION 
Results of the study demonstrated that the average preferred walking speed PWS of subjects 
with CFS was significantly lower than that of the control subjects. The PWS of the CFS 
subjects was around 25% less than the reported normal range of walking speed of 
approximately 1.2m·s-1-1.4m·s-1 [19] whereas control subjects were within the reported range. 
The walking speed of the CFS subjects reported here is lower than that previously reported 
by our group (1.05 & 0.99m·s-1) [6,7]. However in our previous study subjects walked for 
relatively short time and distance. In contrast the present study required subjects to walk 
continuously for five minutes. The PWS of our CFS subjects was higher than that recorded 
by Clapp et al [20] (0.71m·s-1) however these subjects were walking on a motorised treadmill 
rendering direct comparisons questionable.   
In summary those with CFS had a slower walking speed and lower oxygen uptake when 
walking at PWS. Although the relative oxygen uptake requirement for walking was lower in 
those with CFS, when the speed of walking was taken into consideration, the metabolic cost 
of walking in those with CFS was higher than that of controls. The fact that there remained a 
difference between the two groups when the speeds were matched suggests that the relatively 
high energy demands which occur when walking for those with CFS are in some way related 
to the condition itself, or deconditioning associated with the condition, and not just to the 
relatively slow PWS observed.   
 
These results demonstrate that CFS subjects, for whatever reason, adopt a PWS that reduces 
their oxygen uptake but increases the energy cost of walking as measured by oxygen uptake 
per unit distance. This maybe explained by a desire to conserve energy (reduce oxygen 
uptake) and prevent fatigue but has the opposite effect (increase oxygen uptake per unit 
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distance). One possible explanation for this may be kinesiophobia, an excessive and 
debilitating fear of movement which may be a common feature of CFS [21]. Although no 
significant correlation between kinesophobia and maximal exercise capacity has been found 
[18] the presence of kinesiophobia would explain the slow walking speed observed in this 
study. In addition it may be that fear of movement in those with CFS leads, like fear of falling 
in other patient groups, to an increase in muscle activation which in turn increases the oxygen 
demand per unit distance ambulated.  
Higher energy cost of walking may be due to biomechanical or metabolic factors [9]. A 
number of biomechanical factors have been proposed to explain the reason for relatively low 
PWS seen in other patient groups; these factors include poor balance, fear of falling, 
spasticity, joint stiffness [9,22]. There is some evidence that those with CFS may suffer from 
dizziness which is related to orthostatic intolerance [23]. This may lead to impaired balance 
although the consequential effect on gait has not been reported. Indeed our group have 
previously reported no difference between CFS subjects and healthy controls in terms of 
standing balance [6]. 
There is debate within the literature as to the presence and extent of metabolic impairments in 
those with CFS. Some studies have proposed that metabolic differences between CFS and 
control subjects may be due to mitochondrial abnormality. McCully et al [24] reported 
reduced muscle oxidative capacity in those with CFS and suggested this might be due to 
mitochondrial abnormality or deconditioning. Barnes et al [25] argued against mitochondrial 
abnormality but again suggested that observed metabolic differences between CFS and 
control subjects could be explained by deconditioning. It is possible that the present results 
may be partly explained by the presence of deconditioning in those with CFS. Even though  
the IPAQ was used to exclude control subjects with high levels of physical activity and thus 
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to match CFS and control subjects more closely in terms of physical activity profiles it may 
be that overall CFS subjects had lower activity levels than control subjects and, as such an 
increased likelihood of deconditoning. 
A high energy cost of walking can limit the type and duration of everyday activity [26] as 
reflected in the results obtained from the CFS-APQ. These scores suggest that this group of 
CFS subjects experienced limitations in at least some aspects of their daily life and this may 
be due to the increased energy requirements discussed. 
 
Graded exercise and cognitive behavioural therapy are management strategies which may be 
useful for some people with CFS to try to reduce the adverse physiological effects of 
inactivity and possible deconditioning. However exercise in itself can exacerbate the 
symptoms of CFS as exercise performed at too high an intensity can trigger immune 
dysfunction [27]. In order to increase physical activity, reduce deconditioning and reduce the 
physiological cost of walking, whilst avoiding exacerbations, any exercise programme for 
people with CFS should be undertaken under direction of an appropriately qualified 
practitioner. 
Previous research has investigated oxygen uptake per unit distance, or the related energy 
expenditure, in other pathophysiological conditions. Even allowing for the methodological 
differences between the studies the situation appears to be that the physiological cost of 
walking for those with CFS is not very dissimilar to that of other patient groups such as those 
with Multiple Sclerosis [10], Post-poliomyelitis Syndrome [28], patients with orthopaedic 
conditions such as post hip fracture [22] or patients four years following a stroke [9]. 
LIMITATIONS 
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One of the main criticisms of previous research in CFS is that the control subjects are not 
matched to the patient group in terms of their level of activity. In the present study control 
subjects were excluded if they had high levels of activity as determined by the IPAQ. Even 
allowing for that control subjects who were included may have been more physically active 
compared to the CFS subjects. 
As with all studies of this nature one of the limitations of this work is sample size. Whilst 
statistical differences have been shown it would have been advantageous to have larger 
numbers. To achieve a statistical power of 80% based on these data a sample size of 
approximately 35 would be required. As a result of the small sample size and of differences 
in activity levels between the populations the generalisability of these data should be viewed 
cautiously.  
 
CONCLUSION 
The results of this study suggest that the metabolic cost of walking is higher for those with 
CFS compared to their healthy peers and furthermore that the higher energy requirement is 
due in part to the condition itself, or the associated deconditioning, and not solely a reflection 
of the relatively slow preferred walking speed of those with CFS. Whilst the reasons for the 
relatively high energy costs of walking in those with CFS have yet to be fully elucidated, 
ultimately the functional effects appear to be a reduction in activity and participation in 
activities of daily living for those who suffer from this condition. 
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 CFS Control  
Variable Mean SD Range Mean SD Range P 
Age (Years) 49.2 8.4 35 - 64 48 8.4 32 - 64 0.13 
Body Mass (kg) 72.6 11.3 55 - 100 77.3 14.1 55 - 105 0.08 
Height (m) 1.67 0.07 1.59 – 1.77 1.68 0.07 1.53 – 1.76 0.46 
BMI (kgm-2) 26.2 3.5 20.2 – 33.8 27.5 4.5 20 - 40 0.17 
Duration of Symptom (Years) 12.8 6.4 2-24 NA NA NA NA 
Resting VO2 (mLkg-1) 3.2 0.18 2 – 4.4 3.1 0.15 1.8 – 4.2 0.67 
 
Table 1 – Description of subjects, both CFS and control 
 
 
 
